Sernova published its MD&A report, highlighting interim Phase 1/2 type 1 diabetes data from 12 patients showing 8 patients achieving insulin independence, with the first treated patient sustaining insulin independence for more than 4 years. The company said Cohort B uses an optimized 10-channel Cell Pouch with 56% greater islet capacity than the Cohort A device, and it expects confirmatory Cohort C to initiate in H2 2026 pending additional funding. Sernova reported it received FDA authorization for an IND to evaluate Cell Pouch with auto-transplanted thyroid cells in patients undergoing total thyroidectomy for nodular thyroid disease. The company said it plans to use Eledon’s tegoprubart in Cohort C in place of tacrolimus, and noted Eledon reported all six subjects in a separate portal-vein islet transplant trial achieved insulin independence after one or two transplants. Sernova reported a working capital deficit of CAD 24.76 million as of January 31, 2026, and said it expects additional financing initiatives in the near term to continue as a going concern and fund planned R&D.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief on March 16, 2026, and is solely responsible for the information contained therein.
Comments